Plus Therapeutics (PSTV) Price & Analysis

Compare

1,524 Followers

PSTV Stock Chart & Stats

$0.58

-$0.05(-4.03%)

At close: Jan 08 4:00 PM EST

$0.58

-$0.05(-4.03%)

Day’s Range― - ―

52-Week Range$0.16 - $2.31

Previous CloseN/A

Volume69.06K

Average Volume (3M)7.30M

Market Cap

$73.21M

Enterprise Value$56.87M

Total Cash (Recent Filing)$13.29M

Total Debt (Recent Filing)$21.00K

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Feb 19, 2026

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding137,429,060

10 Day Avg. Volume5,867,345

30 Day Avg. Volume7,302,974

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-0.85

Price to Sales (P/S)1.31

P/FCF Ratio-0.71

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue10.82

Enterprise Value/Gross Profit12.17

Enterprise Value/Ebitda-3.52

Forecast

1Y Price Target

$7.75

Price Target Upside1236.21% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.18

Revenue Forecast (FY)$4.12M

Bulls Say, Bears Say

Bulls Say

Commercial LaunchPlus announced the commercial launch of CNSide Cerebral-Spinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay and received reimbursement coverage from United Healthcare.

Coverage AgreementsPlus announced a national coverage agreement with Humana, adding ~16M covered lives for CNSide, combined with the previous UnitedHealthcare agreement, CNSide now has 67M lives under coverage.

Reimbursement ProgressSecuring profitable reimbursement was one of the key factors holding back the prior launch of CNSide, and with the Humana agreement now in place alongside UnitedHealthcare, Plus is making significant progress.

Bears Say

Financial PerformanceThe company reported grant revenues and net loss figures that were below consensus estimates, leading to a lowered 12-month price target.

Geographic Expansion ChallengesCNSide has only been launched in Texas as the company works through licensing and regulatory requirements for other states.

Operational RisksRisks identified for the company include clinical, commercial, partnership, financial, and intellectual property challenges.

Plus Therapeutics News

Plus Therapeutics completes FDA meeting on REYOBIQ development plans

Plus Therapeutics (PSTV) completed a Type B meeting with the U.S. Food and Drug Administration on November 7th...

12h ago

PSTV

Plus Therapeutics’ assay secures national coverage agreement with Humana

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), has signed a national agreement with Humana (HUM), effective...

5d ago

HUM

PSTV

Plus receives additional extension to regain compliance with Nasdasq

Plus Therapeutics (PSTV) announces it has received an additional 180-day extension period from the Nasdaq Listing Qualifications Department...

8d ago

PSTV

Plus Therapeutics highlights ReSPECT-LM trial results at SITC meeting

Plus Therapeutics (PSTV) announces its participation at the 40th Society for Immunotherapy of Cancer, SITC, Annual Meeting, Melanoma...

18d ago

PSTV

Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Plus Therapeutics (PSTV) to $2 from $3 and keeps a...

22d ago

PSTV

Strategic Advancements and Expanding Coverage Propel Plus Therapeutics’ Growth Potential

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Plus Therapeutics, with...

3d ago

PSTV

Plus Therapeutics Gains Nasdaq Extension for Compliance

Plus Therapeutics ( ($PSTV) ) has provided an announcement. On November 17, 2025, Plus Therapeutics announced it received...

8d ago

PSTV

Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning

Plus Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on October 31. Analyst Jason...

21d ago

PSTV

Plus Therapeutics Signs Lease Agreement in Houston

An update from Plus Therapeutics ( ($PSTV) ) is now available. On October 16, 2025, Plus Therapeutics, Inc....

1M ago

PSTV

Plus Therapeutics provides update on CNSide Diagnostic platform launch

Plus Therapeutics (PSTV) announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary,...

1M ago

PSTV

PSTV Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Plus Therapeutics (PSTV) is scheduled to report 3rd quarter earnings on 10/16/2025. Regarding Q3 estimates, Wall Street analysts...

1M ago

PSTV

Buy Rating for Plus Therapeutics Driven by Strategic Advancements and Market Expansion for CNSide Test

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Plus Therapeutics. The associated price target...

2M ago

PSTV

Buy Rating for Plus Therapeutics Driven by CNSide Coverage and Promising Pipeline Developments

In a report released today, Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Plus Therapeutics,...

2M ago

PSTV

Plus Therapeutics announces national coverage agreement with UnitedHealthcare

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), announced that it has signed a national agreement with...

2M ago

UNH

PSTV

PSTV FAQ

What was Plus Therapeutics’s price range in the past 12 months?

Plus Therapeutics lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.

What is Plus Therapeutics’s market cap?

Plus Therapeutics’s market cap is $73.21M.

When is Plus Therapeutics’s upcoming earnings report date?

Plus Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 86 days.

How were Plus Therapeutics’s earnings last quarter?

Plus Therapeutics released its earnings results on Oct 30, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.02.

Is Plus Therapeutics overvalued?

According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Plus Therapeutics pay dividends?

Plus Therapeutics does not currently pay dividends.

What is Plus Therapeutics’s EPS estimate?

Plus Therapeutics’s EPS estimate is -0.03.

How many shares outstanding does Plus Therapeutics have?

Plus Therapeutics has 137,429,060 shares outstanding.

What happened to Plus Therapeutics’s price movement after its last earnings report?

Plus Therapeutics reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went up 1.887%.

Which hedge fund is a major shareholder of Plus Therapeutics?

Currently, no hedge funds are holding shares in PSTV

Plus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

167.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Plus Therapeutics

Plus Therapeutics, Inc. (PSTV) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the development of targeted radiotherapeutics, which leverage the power of radiation to treat tumors while minimizing damage to surrounding healthy tissue. Plus Therapeutics is engaged in advancing its lead product candidates through clinical trials aimed at addressing unmet medical needs in oncology, particularly in the treatment of brain tumors and other solid tumors.

Plus Therapeutics (PSTV) Earnings & Revenues

Historic Earnings Reports

PSTV Stock 12 Month Forecast

Average Price Target

$7.75

▲(1236.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","-1":"-$1","4.75":"$4.75","10.5":"$10.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.75,10.5,16.25,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,2.113846153846154,3.687692307692308,5.2615384615384615,6.835384615384616,8.40923076923077,9.983076923076922,11.556923076923077,13.130769230769232,14.704615384615384,16.27846153846154,17.852307692307694,19.426153846153845,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,1.0946153846153845,1.6492307692307693,2.203846153846154,2.7584615384615385,3.313076923076923,3.867692307692308,4.422307692307692,4.976923076923077,5.531538461538462,6.086153846153846,6.640769230769231,7.195384615384616,{"y":7.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6523076923076924,0.7646153846153847,0.8769230769230769,0.9892307692307692,1.1015384615384616,1.2138461538461538,1.3261538461538462,1.4384615384615385,1.5507692307692307,1.6630769230769231,1.7753846153846153,1.8876923076923076,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >